Skip to main content
DUOPHARMA BIOTECH BERHAD logo

DUOPHARMA BIOTECH BERHAD — Investor Relations & Filings

ISIN · MYL7148OO009 BURSA Manufacturing
Open in API
Filings indexed 73 across all filing types
Latest filing 2026-06-08 Regulatory Filings
Country MY Malaysia
Listing BURSA

About DUOPHARMA BIOTECH BERHAD

https://duopharmabiotech.com/

Duopharma Biotech Berhad develops, manufactures, markets, and distributes a diverse range of pharmaceutical products. Its portfolio encompasses generic drugs, over-the-counter (OTC) medications, and consumer healthcare (CHC) products. The company is a key supplier of essential medicines, including insulin products, to healthcare facilities. Recognized as a leading local manufacturer of generic drugs, Duopharma Biotech prioritizes enhancing healthcare accessibility, driving innovation, and upholding halal leadership. The company is committed to providing smarter solutions for a healthier life through strategic optimization and digital transformation.

Recent filings

Filing Released Lang Actions
OTHERSACCEPTANCE OF TENDER OFFER (HEREINAFTER REFERRED TO AS THE "LETTER OF AWARD" OR "LOA") FOR THE SUPPLY OF RECOMBINANT HUMAN INSULIN 100 IU/ML PENFILL/REFILL AS A PACKAGE (HEREINAFTER REFERRED TO
Regulatory Filings Classification · 70% confidence The document is an announcement by Duopharma Biotech Berhad’s board regarding the acceptance of a government tender offer for the supply of insulin over a three‐year period. It outlines the contract terms, rationale, financial effects, risk factors, and approval requirements. There are no actual financial statements, no change in share capital or M&A activity, no management change, no dividend declaration, etc. This is a general corporate regulatory announcement that does not fit into any specific category, so it falls under the fallback category "Regulatory Filings (RNS)."
2026-06-08 English
MATERIAL LITIGATIONMATERIAL LITIGATION KUALA LUMPUR HIGH COURT CIVIL SUIT NO. WA-22IP-15-02/2025 - WRIT OF SUMMONS AND STATEMENT OF CLAIM SERVED ON DUOPHARMA MANUFACTURING (BANGI) SDN. BHD. (A WHOLLY-
Legal Proceedings Report Classification · 94% confidence The document is an announcement detailing developments in a High Court civil suit filed against a subsidiary, including trial dates and procedural directions. It does not present financial results or request votes, nor is it a report publication. This fits squarely into Legal Proceedings Report, covering updates on significant lawsuits.
2026-06-08 English
Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
Major Shareholding Notification Classification · 90% confidence The document is a regulatory disclosure titled “Changes in Substantial Shareholder’s Interest (Section 138 of CA 2016)” showing an institutional investor (Employees Provident Fund Board) acquiring shares and updating its total shareholding in Duopharma Biotech Berhad. This is a notification of changes in a significant shareholding level, matching the Major Shareholding Notification category.
2026-05-21 English
General Meetings: Outcome of Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled “DUOPHARMA BIOTECH BERHAD 25TH AGM” and contains an “Appendix 3 – Result On Voting By Poll” table showing votes for and against each ordinary resolution. This is the official disclosure of AGM voting results, matching the Declaration of Voting Results & Voting Rights Announcements category.
2026-05-20 English
OTHERSDuopharma Biotech Contributes to National Pharmaceutical Self-Reliance Through Manufacturing Capacity and Portfolio Growth
Earnings Release Classification · 91% confidence The document is a corporate press release summarizing full‐year (FY2025) financial results (revenue, PBT, dividends), business strategy and AGM outcomes. It provides key highlights of the year’s performance rather than the full annual report itself, and it clearly functions as an initial announcement of periodical financial results. Therefore, it best fits the Earnings Release (ER) category. FY 2025
2026-05-20 English
Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
Major Shareholding Notification Classification · 90% confidence The document is an official notice of changes in the interest of a substantial shareholder (Employees Provident Fund Board) under Section 138 of the Companies Act, providing detailed shareholdings before and after the transfer. This matches the definition of a Major Shareholding Notification (MRQ).
2026-05-19 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.